Abstract 5532: Discovery of A-366, a novel small molecule inhibitor that uncovers an unappreciated role for G9a/GLP in the epigenetics of leukemia
Jun Guo(AbbVie (United States)), William N. Pappano(AbbVie (United States)), Chris Tse(AbbVie (United States)), Ramzi F. Sweis(AbbVie (United States)), Bailin Shaw(AbbVie (United States)), Niru B. Soni(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States)), Sujatha Jagadeeswaran(AbbVie (United States)), Marina Pliushchev(AbbVie (United States)), Debra C. Ferguson(AbbVie (United States)), David Maag(AbbVie (United States)), Gary G. Chiang(Therapeutics Clinical Research), Andrew M. Petros(Abbott Fund), Michel Michaelides(Moorfields Eye Hospital), Yupeng He(Guardant (United States)), Alla Korepanova(AbbVie (United States)), Alex R. Shoemaker(Abbott (United States)), Chaohong Sun(AbbVie (United States))
Cited by 0
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 IsMediated by p70S6 Kinase
|Journal of Biological Chemistry|2005|557